Yawancin ƙarin anti‑aging suna ɗauke da manyan alkawari amma shaidar su kadan ne. Wannan an samu shi tare da gwajin bazuwar, jarida mai daraja, da tasirin da ya dace—kasa amma ya isa a tattauna.

A gwajin DO‑HEALTH, gram 1 na omega‑3 a rana ya rage agogo uku na epigenetic a cikin shekaru uku, da kimanin watanni 3 na tsufan halitta. Idan aka haɗa da bitamin D da ƙananan motsa jiki a gida, ya fi kyau a kan agogon PhenoAge.

Tasirin ƙanana ne, kuma an yi binciken a matsayin post‑hoc. Ga abin da bayanan ke nuna da kuma abin da ba su nuna ba.

Abin da gwajin ya yi

Takardar da aka wallafa: Bischoff‑Ferrari HA, Gängler S, Wieczorek M, Belsky DW, et al., "Individual and additive effects of vitamin D, omega‑3 and exercise on DNA methylation clocks of biological aging in older adults from the DO‑HEALTH trial," Nature Aging, 2025;5(3):376‑385 (PubMed, DOI).

Gwajin post‑hoc ne kan mutane 777 daga DO‑HEALTH, wani gwajin bazuwar na manyan mutane daga Switzerland, Germany, Austria, France da Portugal waɗanda suka kai shekaru 70 ko fiye. Gwajin ya yi amfani da zane‑zane 2×2×2, don haka kowanne zai iya samun kowane haɗin guda uku:

• Bitamin D3: 2,000 IU a rana
• Omega‑3: gram 1 a rana (EPA + DHA daga man algae)
• Shirin motsa ƙarfi a gida: sauƙaƙan aiyuka sau 3 a mako

Masana sun auna agogo huɗu na DNA methylation (DNAm) masu zuwa: PhenoAge, GrimAge, GrimAge2, da DunedinPACE. Waɗannan agogo na karanta alamu kimiyyar DNA don tantance shekarun jiki ko gudun tsufa. Lokacin sa‑ido shi ne shekara 3.

Sakamakon da aka samu, tare da lambobi

• Omega‑3 kai‑kai ya rage agogo uku daga cikin hudu: PhenoAge, GrimAge2, da DunedinPACE.
• Haɗin dukkan magungunan uku ya ba da fa'ida mai ƙari kan PhenoAge. Ƙarin kayan haɗi ya nufin ƙarin raguwar agogo a kan wannan agogo.
• Tasirin da aka daidaita ya kai daga 0.16 zuwa 0.32 units daga farkon gwaji zuwa shekara ta 3. Marubuta sun fassara wannan zuwa watanni 2.9‑3.8 na tsufan halitta.

Saurin maƙasudin marubutan shi ne: gwajin ya nuna "tasirin kariya ƙanana na maganin omega‑3 wajen rage tsufan halitta a cikin shekaru 3 a kan agogo da yawa," tare da fa'ida mai ƙari saboda haɗin omega‑3, bitamin D, da motsa jiki a kan PhenoAge.

Watanni uku a cikin shekaru uku ba su nufin juya tsufa ba. Amma alamar ƙanana ce amma tabbatacciya a kan agogo masu yawa, a cikin tsari na bazuwar da ya fi ƙarfi fiye da bayanan kallo ko kananan gwaje‑gwaje da suka gabata.

Me ya sa omega‑3 zai iya yin haka?

Takaitaccen rubutu ya ba da sakamakon agogo, ba dalilin sa ba. Kowace ƙira a nan ra'ayi ne, ba hujja ba. Ana nazarin omega‑3 don tasirinsa kan kumburi da lafiyar metabolism. Waɗannan biyun suna da alaka da hanyoyin halitta da agogo kamar GrimAge2 da DunedinPACE ke lura da su. Ko waɗannan hanyoyi ne suka haifar da canjin alama a DNA har yanzu ba a tabbatar ba.

Fa'idar ƙari a kan PhenoAge ma ban sha'awa. Bitamin D da motsa jiki na iya aiki ta hanyoyi daban‑daban daga omega‑3, wanda zai iya haifar da ƙaruwa idan an haɗa su. Amma takardar ta ambaci wannan ƙari ne kawai a kan PhenoAge, don haka ba za a yi zaton yana aiki ga dukkan agogo ba.

Takaitaccen iyakoki da gaskiya

Wannan ne inda ya kamata ɗaukar maganar ya tsaya:

1. Binciken post‑hoc ne. Tambayar agogo epigenetic ba ita ce manufar asali ba, don haka sakamakon ya fi kama da ƙarfafa ra'ayi fiye da hujja ta ƙarshe.
2. Tasirin ƙanana ne. Girman tasiri na 0.16‑0.32 units, wato kusan watanni 3 a cikin shekaru 3, ba su da girma.
3. Masu gwajin sun kai shekaru 70 ko fiye kuma sun fi lafiya. Ba za a iya tabbatar da tasirin ga matasa ko ga masu cuta mai tsanani ba.
4. Agogo epigenetic alamomi ne na wucin‑gadi. Rage agogo ba yana nufin tsawon rai ko ƙasa da cuta ba. Babu agogo da aka tabbatar zai nuna cewa wata hanya zata tsawaita rayuwa.
5. Ba duk agogo suka motsa ba. Omega‑3 ya tasiri kan agogo uku, kuma ƙarin tasirin an ga shi ne kawai a kan PhenoAge.
6. Sanar da cinikayya. Babban marubucin S. Horvath shi ne wanda ya kafa Epigenetic Clock Development Foundation, ƙungiyar da ke da haƙƙin mallakar fasahar agogo (ciki har da GrimAge), kuma yana aiki a Altos Labs. Sauran marubutan sun bayyana babu wani haɗin sha'awa.

Abin da ya shafi kai: muhimman nasiha na aikace‑aiki

Abubuwan da gwajin ya yi amfani da su:

• Omega‑3: gram 1 a rana (EPA + DHA, man algae a gwajin)
• Bitamin D3: 2,000 IU a rana
• Motsa jiki: sauƙaƙan shirin ƙarfafa gida, sau 3 a mako

Takardar ba ta fayyace lokacin da ya fi dacewa ba, don haka babu wani “hacks” na lokaci da aka tabbatar; ainihin sakamakon yana nuni da amfani na kullum tsawon shekaru 3, ba na lokaci‑ƙan gajeren ba.

Waɗanda zai iya amfana: manya masu shekaru 70 da sama waɗanda suke da lafiya gaba ɗaya—wannan shine rukuni da aka nazarta. Matasa masu son bio‑hacking na iya ganin bayanan da ban sha'awa, amma ba a tantance tasirin a kansu ba.

Waɗanda ya kamata su yi la’akari ko su tuntuɓi likita kafin su fara:

• Duk wanda ke shan magungunan rage jini ko wasu magungunan antiplatelet ya kamata ya tattauna da likita kafin ƙara omega‑3.
• Duk wanda ke da cuta, yana shan magunguna da yawa, ko yana da takunkumin kari da ya shafi ɗanɗano ya kamata ya nemi shawarar ƙwararre. Kashi na bitamin D musamman yana bukatar a saita tare da likita idan akwai matsalolin calcium.
• Idan kana da rashin jituwa da ƙifi ko kayan teku, duba asalin omega‑3 da kake sha; gwajin ya yi amfani da man algae.

Tsaro: adadin da aka yi amfani da su (gram 1 na omega‑3, 2,000 IU na bitamin D3) suna da matsakaici, amma wannan taƙaitaccen bayani ba ya kunshe da cikakken bayanin tsaro na gwajin, don haka shawara ta sirri daga ƙwararren likita har yanzu tana da muhimmanci.

Karshe

Idan kana neman ƙara tsada‑kasa na uzun rayuwa da hujja, wannan gwajin ya ba da hujja na ƙwarai, ko da dai ba babba ba: omega‑3 ya rage agogo da dama na tsufan halitta a cikin yanayi na bazuwar, kuma haɗawa da bitamin D da motsa jiki a gida ya ƙara inganta PhenoAge. Amma ribar na kusan watanni 3 a cikin shekaru 3 ne, binciken post‑hoc ne, mahalarta na manya ne masu lafiya, kuma agogo ba su wakilci sakamakon rayuwa ba. Ka ɗauke shi a matsayin alamar ƙanana mai fa'ida, ba ruwan wanka na matasa ba, kuma ka tabbatar ya dace da yanayin lafiyarka ta hanyar tuntuɓar likita.